Kennedy Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Kennedy Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.28M	Sell	23,549 -289	-1%	-$67.5K	0.11%	287
2026 Q1	$5.45M	Buy	23,838 +3,976	+20%	+$891K	0.12%	277
2025 Q4	$4.24M	Buy	19,862 +123	+0.6%	+$25.4K	0.09%	325
2025 Q3	$3.92M	Buy	19,739 +1,111	+6%	+$207K	0.09%	336
2025 Q2	$3.22M	Buy	18,628 +16,078	+631%	+$2.62M	0.08%	364
2025 Q1	$397K	Buy	+2,550	New	+$364K	0.01%	596

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Kennedy Capital Management's ASND Position: Q2 2026 in Review

Kennedy Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 1.2% in Q2 2026, selling an estimated $67.5K and leaving 23,549 shares worth $6.28M. The position accounts for 0.11% of the portfolio, ranked #287.

Kennedy Capital Management first reported a position in ASND in Q1 2025 and has held it in 6 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Kennedy Capital Management held 23,549 shares of Ascendis Pharma A/S worth $6.28M as of Q2 2026.
Kennedy Capital Management sold 289 Ascendis Pharma A/S shares in Q2 2026, an estimated $67.5K.
Ascendis Pharma A/S made up 0.11% of Kennedy Capital Management's portfolio in Q2 2026, its #287 holding.
Kennedy Capital Management first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 6 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.